MicroRNAs (miRNAs) regulate gene expression post-transcriptionally and thus are involved in various physiological and pathological states. Due to their stability in biofluids miRNAs have also been proposed as biomarkers (BMs) for tissue injury. We investigated the usefulness of urinary miRNAs for detection of site-specific renal damage in an antiglomerular basement membrane glomerulonephritis (GN) model in rats by comparing GN-induced urinary miRNAs profiles to traditional and newer protein BMs, and to proximal tubular injury-induced urinary miRNA profiles observed previously after cisplatin (Cp) treatment. Male Wistar Kyoto and Sprague Dawley rats were dosed once with 1, 2.5, and 5 ml/kg nephrotoxic serum (NTS) or 1.5 and 5 ml/kg NTS, respectively. GN and tubular damage were observed histopathologically in all treated rats after 14 days. Although serum creatinine and BUN were not changed, several protein BMs and 74 urinary miRNAs were found to be increased 8 and 14 days after NTS administration. Of these 74 miRNAs, 5 were identified as increased after NTS but not after Cp treatment. Using in situ hybridization two of them, miR-10 b and -100, were found to be localized in distal segments of the nephron, potentially reflecting the tubular injury in those regions. Furthermore, evaluation of both miRNA and mRNA expression in the kidney revealed possible miRNA-mRNA interactions mostly associated with fibrotic and transforming growth factor b signaling. In conclusion, our investigations support the potential of urinary miRNAs as specific BMs for kidney injury, and suggest a role of miRNAs in pathological processes during GN in the kidney.
Detection of kidney injury is a challenge either in preclinical and clinical phases of drug development or in patients with acute kidney injury (AKI) caused by other reasons, because especially in the latter case patients are at high risk to develop chronic or end-stage renal diseases (Guengerich, 2011; Hsu et al., 2013) . As traditional biomarkers (BMs) for kidney function, such as serum creatinine and blood urea nitrogen are associated with low sensitivity, specificity, and capability for early diagnosis (Vaidya et al., 2008) , large efforts were and are still being undertaken in the exploration of new kidney injury BMs with enhanced characteristics. Significant success was achieved within the protein BM research leading to regulatory qualification of new BMs in urine for detection of nephrotoxicity in rats (EMA, 2009) . Although these new protein BMs outperform traditional BMs in sensitivity and specificity, they are partly limited for instance in terms of antibody availability to ensure translatability across preclinical laboratory animal species and to humans (Jensen, 2004) or in terms of stability in biofluids (Dieterle and Sistare, 2010) . In addition, none of these is exclusively specific for glomerular injury.
Recently another molecule class, microRNAs (miRNAs), has entered the BM research field. Accumulating evidence suggests them as promising new BMs for tissue injury. MiRNAs are small (approximately 22 nucleotides), noncoding RNAs known to post-transcriptionally regulate gene expression through binding to 3 0 -untranslated region of target mRNAs (Bartel, 2004) . They are evolutionarily conserved across a wide range of species and involved in essential physiological functions, including proliferation, apoptosis, and differentiation (Krol et al., 2010) . Not unexpected in light of their wide range of functions, miRNA involvement was identified in various pathological states, such as cancer, cardiovascular, and kidney diseases (Hermeking, 2012; Schena et al., 2014; Small and Olson, 2011) . With the discovery of miRNAs in body fluids (Weber et al., 2010) their features as ideal BMs were recognized: tissue-specificity, lessinvasive accessibility, high stability in biofluids, translational potential, and sensitive quantification with real-time PCR (Mall et al., 2013; Saikumar et al., 2014) . Several studies have already reported the BM potential of, eg, plasma miRNAs for the detection of cancer (Fu et al., 2014) , drug-induced liver injury (Wang et al., 2014) , or myocardial injury (Nishimura et al., 2015) . Compared to reports on bloodbased miRNAs as potential BMs, data for urinary miRNAs as candidate BMs for kidney damage are limited, yet still promising, as suggested by studies analyzing urine of patients with AKI or immunoglobulin A nephropathy (Ramachandran et al., 2013; Saikumar et al., 2012; Wang et al., 2011) .
Recently, the Health and Environmental Science Institute (HESI) (HESI is a nonprofit institution whose mission is to engage scientists from academia, government, and industry to identify and resolve global health and environmental issues) Biomarkers of Nephrotoxicity Committee engaged into investigation of the potential of miRNA measurements in urine for detection of site-specific renal damage, studying compounds with known specific toxic effects on discrete segments of the nephron in a precompetitive collaboration. In a first study we examined the miRNA profile in urine from Wistar rats with cisplatin (Cp)-induced proximal tubular injury and found many miRNAs with significantly increased urinary levels upon Cp treatment (Pavkovic et al., 2014a) . These results were confirmed by other HESI Committee members reporting several identical miRNAs to be increased in urine after Cp-and gentamicininduced proximal tubular injury in Sprague Dawley (SD) rats (Kanki et al., 2014; Nassirpour et al., 2014) .
The objective of this study was to investigate urinary miRNA levels in a rat injury model affecting a different part of the nephron, ie, the glomerulus and to identify site-specific miRNAs by comparing urinary miRNA profiles after glomerular versus proximal tubular injury. Therefore, we employed nephrotoxic serum (NTS) which contains antibodies against the glomerular basement membrane (GBM) to induce glomerulonephritis (GN). Anti-GBM GN models in rats are widely used as its biochemical and histopathological characteristics are similar to crescentic nephritis and Goodpasture's disease in humans (Pusey, 2003) ; although, such models are challenging as tubular damage is a known side effect of antiserum-induced GN models (Salant and Cybulsky, 1988) . To our knowledge, this is the first time that urinary miRNA was profiled in an anti-GBM GN model. Urine was collected 8 and 14 days after a single injection of 1, 2.5, and 5 ml/kg NTS in male Wistar Kyoto (WKY) rats and of 1.5 and 5 ml/kg NTS in male SD rats. In addition to analyses of classical endpoints and several newer protein BMs, urinary miRNA profiles were measured by quantitative real-time PCR. Potential site-specific localization of two miRNAs apparently specific for the injury present in the GN model was investigated by in situ hybridization (ISH). Furthermore, as different rat strains show differential susceptibility to NTS-induced GN, two different rat strains were chosen for characterization of molecular processes affected in this model, by investigating gene expression in the kidneys from both rat strains.
MATERIALS AND METHODS
Animal studies. All animal experiments were performed according to the German guidelines for care and use of laboratory animals. Male WKY and SD rats, 8 weeks old, were purchased from Charles River laboratories (Sulzbach, Germany). Animals were individually housed in type III makrolon cages, with a 12-h light-dark cycle. Standard rodent chow pellets and water were provided ad libitum.
Rats were randomly grouped (WKY: control group n ¼ 3, treatment groups n ¼ 5; SD: all groups n ¼ 6) and dosed once iv with 0, 1 (WKY), 1.5 (SD), 2.5 (WKY), or 5 ml/kg NTS (Sheep AntiRat GBM Serum [PTX-001S]; Probetex, San Antonio, Texas). Control groups received appropriate volumes of normal saline solution. Doses were selected based on Probetex recommendations and dose finding studies performed in house. For urine collection animals were housed in individual metabolism cages (24 h) and had access to food and water. Urine was collected over ice on day 8 and 14, centrifuged (3000 Â g 10 min 10 C) and the supernatant was stored at À80 C. Blood was collected on day 14, and resulting serum and plasma were stored at À80 C.
On day 14 rats were euthanized and the kidneys were removed for histopathological examination and RNA isolation. Kidney tissue for RNA isolation was shock frosted with liquid nitrogen and stored at À80 C.
Biochemical and histopathological analyses. Blood urea nitrogen and serum creatinine concentrations were measured with an ADVIA 1650 using reagents from Siemens Diagnostics (Fernwald, Germany). Creatinine was determined by the Jaffe method. Urinary total protein was determined quantitatively with an ADVIA 2400 using reagents from Siemens Diagnostics. Urinary creatinine was measured using an enzymatic test on a Roche Cobas cIII. Urinary protein BMs were analyzed with two different platforms according to the manufacturer's instructions. MesoScale Discovery (Gaithersburg, Maryland): urinary albumin (ALB) was measured with the Kidney Injury Panel 1 Assay Kit. Luminex xMAP (purchased from Novagen, EMD Chemicals, Madison, Wisconsin): urinary b-2-microglobulin (b2M), glutathione-S-transferase alpha (aGST), kidney injury molecule-1 (KIM-1), tissue inhibitor of metallopeptidase-1 (TIMP-1), vascular endothelial growth factor (VEGF), and calbindin (CALB), clusterin (CLU), cystatin C (CysC), lipocalin-2 (neutrophil gelatinase-associated lipocalin, NGAL), osteopontin (OPN) were measured with the WideScreen Rat Kidney Toxicity Panels 1 and 2, respectively. Absolute concentrations were normalized to the corresponding urinary creatinine concentration. Statistical analysis was performed with ANOVA and Dunnett's test or with the Student's t test using GraphPad Prism 5 (GraphPad Software Inc) between replicates of the treatment groups and corresponding timematched control group.
For histopathological examination, kidneys were fixed infibrosis, and mononuclear cell infiltration) were graded separately per parameter using a severity scoring system: grade 0, absent; grade 1, minimal; grade 2, slight; grade 3, moderate; grade 4, marked; grade 5, very severe. To further characterize the lesion a Periodic acid-Schiff (PAS) reaction stain was performed, too. Additional findings in the SD rats, included cysts, tubular basophilia, and pelvic dilation, these findings were interpreted to be spontaneous background findings.
RNA extraction. Total RNA including small RNA species (miRNAs) was isolated from 200 ml urine using the miRNeasy Mini Kit (Qiagen, Hilden, Germany). Each urine sample was mixed with 700 ml QIAzol, and then spiked with 2.5 fmol synthetic control miRNA ath-miR-159a (Sigma Aldrich, Hamburg, Germany); all following procedures were performed according to the manufacturer's instructions. Finally, RNA was eluted with 40 ml RNase-free water. Total kidney RNA including small RNA species was also isolated with the miRNeasy Mini Kit from 20 mg kidney tissue, whereas total kidney RNA (mRNA) was isolated with the RNeasy Mini Kit (Qiagen) from 70 mg kidney tissue, both according to the manufacturer's instructions.
The quality of isolated RNAs was assessed using Bioanalyzer Small or Pico RNA Kits (Agilent, Santa Clara, California), and the quantity was determined with a spectrophotometer.
Quantitative real-time PCR and data analysis. Urinary miRNA profiles were analyzed with TaqMan Low Density A Arrays (TaqMan cards; Applied Biosystems by life technologies, Darmstadt, Germany), representing 373 unique rodent miRNAs and several small RNAs. A fixed volume of 3 ml of the RNA eluate was employed. Megaplex reverse transcription, megaplex preamplification, and final quantitative PCR on the TaqMan cards were performed according to the manufacturer's instructions. MiRNA levels were calculated according to the "modified DCt quantification" approach as described previously (Pavkovic et al., 2014a) . This approach is based on calculating 2 30-Ct and normalizing to urinary creatinine (uCrea) (2 30-Ct /uCrea) to derive a unit-less absolute amount, corrected for urine dilution. For selection of affected miRNAs derived from the TaqMan card data, tools implemented in Analyst software (Genedata, Basel, Switzerland) were employed, including ANOVA with factors treatment and time (BH-Q < 0.05 considered as significant), Student's t test (treated vs control, p < .01 considered as significant), and a 2-fold change cutoff between treated and control groups.
Selected miRNAs were re-analyzed in urine samples with TaqMan MicroRNA Assays followed by absolute quantification using standard curves run in parallel, as described previously (Pavkovic et al., 2014a) . For several miRNAs for which we did not obtain a reliable standard curve with TaqMan MicroRNA Assays, we used miCURY LNA PCR assays from Exiqon (Vedbaek, Denmark). A fixed volume of 2 ml of the RNA eluate was employed for these assays. Universal reverse transcription followed by a specific SYBER green-based quantitative PCR were conducted according to the manufacturer's instructions.
Kidney miRNAs were measured with TaqMan cards according to the manufacturer's instructions. Relative levels of kidney miRNAs (treated vs control) were calculated using the general DDCt method with small RNA U6 as endogenous control gene:
Tools available via Genedata's Analyst software, including Student's t tests (treated vs control, p < .05 considered as significant) and a 1.5-fold change cutoff between treated and control groups, were used for selection of deregulated miRNAs.
Microarray expression profiling. Biotin-labeled copyRNA samples prepared from 500 ng high quality total kidney RNA were hybridized on GeneChip Rat genome 230_2.0 arrays (Affymetrix, Santa Clara, California) according to the manufacturer's instructions. After scanning of the fluorescent GeneChip images with the Affymetrix GeneChip Scanner 3000, raw data image files (dat) were converted into cel-files. Finally, one intensity value per probe set was derived with Affymetrix Microarray Suite (MAS) 5.0. The GeneChip Rat genome 230_2.0 array comprises over 31 000 probe sets representing approximately 28 700 wellannotated rat genes.
Using Genedata's Analyst, genes encoding mRNAs, whose levels were significantly changed, were selected separately for each rat strain using ANOVA based on the factor treatment (BH-Q < 0.005 considered as significant), Student's t test (p < .001 considered as significant), and a 2-fold deregulation cutoff between treated and control groups.
Ingenuity pathway analysis (IPA, Ingenuity Systems, www. ingenuity.com) was employed for pathway analysis in general and to search for deregulated mRNAs containing sequences complementary to those present in the deregulated miRNAs, ie, so-called miRNA target analysis for identification of mRNAs potentially regulated by miRNAs. The following filter criteria were applied: (1) experimentally observed and/or highly predicted target relation, ie, sequence complementarity between a mRNA and a miRNA, (2) opposite direction of expression change after NTS administration, because miRNAs are mostly negative regulators of the mRNAs they can bind, and (3) known expression of the miRNAs in kidney.
In situ hybridization. In a separate experiment, the localization of selected miRNAs was investigated in the kidney of a healthy male Wistar rat. After whole-body perfusion with a fixing solution containing 3% formalin and 1% glutaraldehyde, kidneys were immediately removed, fixed in neutral buffered formalin, trimmed and paraffin embedded. ISH was performed on approximately 5-mm thick sections using double-digoxigenin (DIG) labeled miRNA probes from Exiqon according to the manufacturer's instructions with minor modifications. In brief, sections were first deparaffinized with xylene and ethanol (100, 96, and 70%) followed by incubation with proteinase-K (2.5 mg per slide for 10 min 37 C). After washing with 1 Â PBS, sections were dehydrated with ethanol (70, 96, and 100%), air dried for 15 min, and prehybridized for 30 min at 55 C with 1 Â Exiqon's hybridization buffer supplemented with 4.3% salmon sperm DNA (Sigma-Aldrich). Hybridization with the miRNA probes (miR10b: ACACAAATTCGGTTCTACAGGG, Tm 82 C, 100 nM; miR-100:
CACAAG-TTCGGATCTACGGGTT, Tm 83 C, 100 nM; miR-26a:
AGCCTATCCTGGATTACTTGAA, Tm 85 C, 100 nM; miR-192:
GGCTGTCAATTCATAGGTCAG, Tm 83 C, 80 nM) was performed for 1 h 30 C under the RNA melting temperature corresponding to the optimal hybridization temperature. Sections were washed sequentially with preheated SSC-buffer (1Â, 0.2Â, 0.1Â) at 55 C and blocked with blocking buffer (1% BSA, 2% sheep serum in 0.1% PBS-T) for 30 min at room temperature. Alkaline phosphatase (AP) conjugated anti-DIG (Roche Diagnostics, Mannheim, Germany) was diluted 1:800 in antibody-dilutionbuffer (1% BSA, 1% sheep serum in 0.05% PBS-T) and incubated for 1 h at room temperature. After washing with 0.1% PBS-T, sections were incubated with AP-substrate solution (NBT-BCIP ready-to-use tablets; Roche Diagnostics) light-protected over night at room temperature. The AP reaction was stopped with cold water. For counter staining, sections were incubated in 0.01% eosin for approximately 1 min, dehydrated with ethanol (70, 90, and 100%), and then xylene. Finally, sections were scanned and analyzed using the MIRAX Scanner and Viewer, respectively (Zeiss, Jena, Germany). General experimental settings were established with Exiqon's positive controls (U6 probe: abundant nuclear signal; miR126 probe: abundant endothelial signal) and negative controls (scrambled probe: no complementarity to any known miRNAs sequence). The pictures shown are representative for at least 3 independent ISH experiments.
Results
Histopathology and Clinical Chemistry WKY and SD rats were treated once with different doses of NTS. The WKY kidneys were histologically examined after 14 days. GN, characterized by mesangial hypercellularity, glomerular matrix accumulation, and Bowman's capsule hyperplasia, was diagnosed in all NTS-treated rats (Fig. 1) . Furthermore, an accumulation of PAS positive material in the mesangium was seen in both rat strains ( Supplementary Fig. 2 ). Although fully formed glomerular crescents were not detected, the activation/hyperplasia of the Bowman's capsule epithelia (hyperplasia) might represent dose dependent initial lesions of crescent formation and/or the hypercellularity might develop/contribute to crescent formations in a later stage. All findings increased dose-dependently from minimal to moderate severity scores, and were not observed in control rats. In addition to glomerular changes, tubular degeneration and regeneration was observed in the cortex including the corticomedullary junction and extending to the inner stripe of the outer medulla. Treated SD rats, examined 8 and 14 days after NTS injection, showed comparable findings, but glomerular changes were less severe than in WKY rats, whereas tubular damage and intragroup variability were larger. All histopathological findings are listed in Supplementary Table 1. Traditional kidney injury BMs, such as blood urea nitrogen and serum creatinine were not increased after NTS treatment ( Supplementary Figs. 1A and 1B ), but severe proteinuria was detected. Eight and 14 days after NTS administration, total protein levels were significantly and dose-dependently increased in urine from WKY and SD rats (Fig. 2) .
Evaluation of Urinary Protein BMs for Kidney Injury
For measurement of newly qualified, recently endorsed, or exploratory protein BMs urine was collected 8 and 14 days after NTS treatment. Corresponding to severe proteinuria a large increase of ALB was measured in urine from all treated rats of both strains at both time points (Table 1) . b2M, KIM-1, CLU, and CysC showed similar urinary profiles: no increase after treatment with the lowest doses in both rat strains on both days, an increase after treatment of WKY rats with the middle dose of 2.5 ml/kg NTS on both days, and a significant increase after treatment with the high dose (5 ml/kg) in both rat strains on both days (Table 1) . None of the other BMs, ie, NGAL, OPN, aGST, TIMP-1, or VEGF, were increased in urine after treatment with the lowest doses in both rat strains, and after treatment of WKY rats with the middle dose of 2.5 ml/kg NTS; only NGAL and VEGF were significantly increased on day 14 and 8 NTS (Table 1 and  Supplementary Table 2) , respectively. Treatment with 5 ml/kg NTS increased urinary levels of all other BMs, except CALB which showed no significant changes in urinary levels at any time point. Overall, the NTS-induced increases of all urinary BM levels were dose-dependent, larger on day 8 than on day 14 per dose group and higher in WKY rats than in SD rats. Interestingly, despite both ALB and KIM-1 showing a strong treatment-dependent increase in urine, the treatment versus control ratios were clearly higher for ALB than for KIM-1, eg, approximately 140-fold higher 14 days after treatment of WKY rats with 5 ml/kg NTS. 
Comparison of Urinary MiRNAs Increased by GN-Associated Versus Cp-Induced Proximal Tubular Injury
To explore miRNAs increased or decreased in urine with GNassociated kidney damage, we measured over 350 miRNAs in urine samples from control and NTS (5 ml/kg) groups on day 8 and 14 using TaqMan cards. After statistical analysis, in total 74 miRNAs were found showing significantly increased levels in urine from WKY (72 miRNAs) and SD (30 miRNAs) rats after NTS treatment ( Supplementary Fig. 4 ). The miRNA increases were higher and displayed less intragroup variability in urine from WKY than from SD rats (Supplementary Table 3 ). For further analysis we selected 12 miRNAs: miR-10a, -10b, -21, -26a, -34a, -34b, -100, -184, -192, -197, -211, and -486 . The selection was based on 2 main considerations: known expression in the glomerulus or at least in the kidney and either increased or not increased in urine compared with previously reported urinary miRNA profiles after Cp-induced proximal tubular injury (Pavkovic et al., 2014a) . The latter consideration refers to the identification of miRNAs potentially specific for one kidney etiology, here proximal glomerular versus tubular injury. Candidates were derived from a comparison of GN-and Cpaffected urinary miRNA groups (Fig. 3) , which were essentially all increased in urine by the respective treatment ( Supplementary Fig. 2 and Pavkovic et al., 2014a) . In the Cp study we identified in total 136 significantly affected miRNA in urine after a single administration of 3 mg/kg with analysis 3, 5, 8, 15, and 24 days thereafter. Maximal necrosis had been detected histopathologically 8 days after Cp treatment. In total, 68 urinary miRNAs of the 74 NTS-and 136 Cp-increased urinary miRNAs were identical. Although then 68 miRNAs appeared to be specifically increased by Cp, a qualitative examination of the profiles of these miRNAs after NTS treatment revealed that they were also increased in the GN rat models (data not shown). Still, 5 of the 6 miRNAs increased in a significant manner only by NTS (miR-10a, -10b, -100, -211, and -486) remained as apparently specific for NTS-induced injury after inspection of the profile of these miRNAs in urine from Cp-treated rats, ie, appeared not consistently affected by Cp. They were thus selected for further analysis together with 7 other miRNAs. For verification of their profiles derived from TaqMan card PCR, absolute urinary concentrations were measured using single miRNA-specific TaqMan or Exiqon assays with standard curves run in parallel which currently represents a reliable and accepted method for urinary miRNA quantification. Applying standard curve quantification most of the 12 urinary miRNA increases after 5 ml/kg NTS seen before with TaqMan card measurement could be verified. For 9 miRNAs the increases were also statistically significant in WKY rats after treatment with the highest dose of NTS on either day 8 (7 miRNAs) or 14 (4 miRNAs), with 2 miRNAs significantly increased at both time points. In SD rats only miR-21 was also found significantly increased 8 days after treatment (Table 2) . Comparison with our Cp data showed that 4 of these 12 selected miRNAs, miR-21, -34a, -184, -192, were clearly increased after NTS and Cp treatment based on the measurement of absolute urinary concentrations in both studies. The increase of the 5 miRNAs, miR-10a, -10b, -100, -211, -486, which seemed to be specifically increased after NTS treatment only based on TaqMan card data, could also be verified with standard curve quantification for WKY rats after NTS treatment. We additionally measured the selected miRNAs in urine samples from rats treated with lower NTS doses. In urine from WKY rats treated with 2.5 ml/kg NTS only miR-10a (1.4-fold) and miR-21 (4.6-fold) were significantly increased on day 8 (Table 2) . MiR-10b and -100, although not significant in 3 of 4 cases, appeared strongly increased in urine from WKY rats treated with 2.5 and 1 ml/kg NTS after 14 days. In urine from SD rats treated with 1.5 ml/kg NTS clearly increased miRNAs were not detected ( Table 2 ). The increase of urinary miRNAs after lower NTS doses correlates with increased levels of several protein BMs. Except for ALB, none of the protein BMs was significantly increased after the lowest doses of 1 and 1.5 ml/kg NTS in WKY and SD rat urine, respectively. Yet a few did show higher levels after 2.5 ml/kg NTS in urine from WKY rats (Table 1) .
Distinct Localization of miR-10b and 100 in the Rat Kidney ISH experiments were performed to investigate where in the normal kidney those miRNAs are expressed which were found to be specifically increased by NTS-induced GN but not Cpinduced proximal tubular injury. We used untreated and not treated kidney, as the latter may be of insufficient quality for detection of ISH signals, and as the knowledge of the localization of a miRNA in normal kidney should allow to infer the damage location if such a miRNA is increased in urine after a toxic treatment, provided that this miRNA is not induced at the expression level in another location by the toxic treatment. Based on this observation we hypothesized the 5 miRNAs listed above, ie, miR-10a, -10b, -100, -211, and -486 to be localized in glomeruli within the kidney, as this should be the primary damage site impacted by NTS treatment. For initial evaluation we selected miR-10b and -100 as they were most increased in urine after NTS treatment (Table 2 ) but were not changed in the kidney tissue (Supplementary Table 6 ). With U6 and miR-126 as positive controls, we observed the expected nuclear and endothelial staining, respectively (Figs. 4A and 4B), whereas no staining was observed with the negative control (Fig. 4E) , establishing that the protocol used can detect site-specific localization of a miRNA. Furthermore, miR-26a and -192, which are known to be expressed in kidney, were both detected in glomeruli and proximal tubules (Figs. 4C and 4D) . Unexpectedly, in the normal rat kidney miR-10b and -100 expression was localized in distal segments of the nephron, more precisely in the descending thin limb of the loop of Henle, the distal convoluted tubule, the connecting tubule, and the cortical collecting duct; but not in glomeruli (Fig. 5 ).
mRNA and miRNA Patterns Associated with Rat Kidney GN For elucidation of molecular pathways which may play a role or may be associated with NTS-induced GN and to potentially identify a molecular basis for different strain susceptibility, mRNA and miRNA levels were examined in the kidney 14 days after NTS administration in both rat strains. Gene, ie, mRNA expression measured with Affymetrix GeneChip microarrays resulted in 428 and 40 significantly deregulated mRNAs in kidneys from WKY and SD rats, respectively; yielding in total 439 mRNAs deregulated in both strains together (data not shown). Gene expression profiles were comparable within the two rat strains in terms of direction of deregulation and dose dependency ( Supplementary Fig. 4 ). In total, 253 of the 439 deregulated genes could be functionally assigned to categories, such as inflammation, proliferation, regeneration, structural remodeling, and others (Supplementary Table 4 ). The categories with the highest numbers of genes assigned to them were inflammation with mRNAs coding for, eg, interleukin-24 or CD53, and regeneration with mRNAs coding for, eg, different collagens like Col1a1 or collagen 4a1 (Col4a1). Two mRNAs were oppositely changed by NTS treatment in the two rat strains, being decreased in kidneys from SD rats but increased in kidneys from WKY rats. Both proteins encoded by these mRNAs are associated with immune response/inflammation: RT1 class II, locus Ba (Rt1-Bb), and complement component 6 (C6) ( Supplementary Fig. 4 and Supplementary Table 4) .
Because NTS effects were more prominent in WKY than in SD rats, we focused on WKY rats for miRNA analysis. Kidney miRNA levels measured with TaqMan cards resulted in 80 significantly deregulated miRNAs after NTS administration 1.1 6 0.7 4.6 6 4.7* 1.2 6 0.5 4.2 6 1.1* 2.8 6 0.6** 0.78 6 0.25 1.02 6 0.41 5.81 6 4.40** 2.26 6 1.64 miR-192 TM 1.6 6 1.4 2.3 6 2.0 1.9 6 1.7 1.8 6 0.5 1.7 6 0.6 3.9 6 2.1* 0.31 6 0.18** 0.84 6 0.59 2.80 6 3.04 2.12 6 1.46 miR-26a EQ 1.5 6 0.5 1.3 6 0.4 1.9 6 0.7 1.2 6 0.7 1.0 6 0.3 1.6 6 0.2** N/M miR-34a TM 4.5 6 3.3 5.4 6 3.9 1.1 6 1.1 2.0 6 2.8 4.0 6 2.6 2.0 6 0.3 0.58 6 0.37 1.37 6 0.81 0.59 6 0.46 1.16 6 0.79 miR-34b TM 5.3 6 7.3 2.5 6 3.4 2.8 6 3.6 0.5 6 0.2 4.2 6 2.6 1.3 6 0.5 0.43 6 0.52 0.94 6 0.61 4.75 6 3.69 1.78 6 1.76 miR-184 TM 1.9 6 1.6 5.8 6 5.1 1.0 6 1.0 2.8 6 2.7 2.7 6 1.5 6.0 6 7.0 0.21 6 0.13** 0.60 6 0.32 0.73 6 0.48 2.52 6 2.96
a Apparently NTS-specific.
Shown are treated versus control ratio means 6 standard deviation of urinary miRNA levels after injection of WKY and SD with NTS (WKY: control n ¼ 3, treated n ¼ 5;
SD: n ¼ 6) derived from urinary creatinine normalized absolute miRNA concentrations. Statistical analysis was performed with Student's t test, and statistical significance is indicated by *p < .05, **p < .01, and ***p < .001 compared with time-matched control groups. N/M, not measured; E, measured with Exiqon's PCR assays; T, measured with TaqMan PCR assays.
(Supplementary Table 5 ). Some of the miRNAs increased in urine were found to be increased (miR-21, -34b, -146b, -197) or decreased (miR-192, -193b) in kidneys after NTS treatment. To identify possible regulatory influences of miRNAs on mRNAs in the kidney during GN, we employed tools implemented in the IPA software. Within the pool of 439 significantly deregulated mRNAs in the kidney after NTS treatment, we identified 69 mRNAs that could potentially be targeted by 44 of the 80 deregulated kidney miRNAs (Supplementary Table 7 ). These mRNAs encode proteins associated with, eg, fibrosis or the transforming growth factor b (TGFb)-pathway and the corresponding miRNA-mRNA pairs mostly showed the expected opposite direction of change (Figs. 6A and 6B ). For example, increased levels of miR-197 and -132 could be associated with decreased levels of insulin-like growth factor binding protein 3 (Igfbp3) and matrix metallopeptidase 9 (Mmp9) mRNAs, respectively, in the kidney after NTS-induced GN (Fig. 6A ).
Discussion
To investigate whether miRNAs could complement or enhance urinary protein BMs with respect to diagnosis of glomerular kidney injury, urinary miRNA profiles were examined in a GN model in two rat strains. The study encompassed administration of WKY and SD rats with different doses of NTS, followed by measurement of traditional and newer protein BMs 8 and 14 days after treatment, and histological examination of the kidneys 8 (SD only) and 14 days after treatment. Urinary miRNA profiles obtained with this GN model were then compared with previously reported urinary miRNA profiles after Cpinduced proximal tubular injury to search for miRNAs specifically associated with glomerular damage. To reveal potential involvement of miRNA-mRNA pairs in GN-induced kidney damage, miRNA and mRNA expression was examined in the kidney. Although traditional BMs did not indicate kidney damage, confirming their insensitivity (Urbschat et al., 2011) , both glomerular and tubular damage were observed histopathologically on day 14. Tubular damage was a secondary response to glomerular changes, because the latter can lead to protein overload in primary urine and thus to injury in exposed tubules (Togashi et al., 2013) . The severity of tubular damage indicates potential primary tubular injury, possibly due to reabsorption of the NTS or cross-reactivity of the polyclonal antibodies in the NTS with tubular structures. We suspect onset of tubular damage already on day 8, as seen for SD rats and as KIM-1, a qualified protein BM for proximal tubular injury (Vaidya et al., 2010) , was even higher in urine on day 8 compared with day 14 in WKY rats. Tubular damage was probably also the reason for increased levels of other protein BMs most of which are qualified for proximal tubular injury (Fuchs and Hewitt, 2011) .
In parallel to proteinuria, ALB was the only protein BM in urine clearly increased after all NTS doses in both rat strains.
ALB indicates loss of glomerular integrity and/or impaired proximal tubular function (Swain et al., 2011) . It was increased after both Cp-induced tubular injury reported earlier (Pavkovic et al., 2014b) and NTS-induced GN reported here, indicating that as expected urinary ALB alone is not sufficient for differentiation between tubular versus glomerular injury. We still suggest that treatment-induced increases of urinary ALB in relation to that of proximal tubular specific urinary KIM-1 can serve to localize the primary site of injury, because in our data ALB versus KIM-1 ratios were much higher in the GN study associated with glomerular (and tubular) injury compared to the Cp study with tubular injury, only.
Using a PCR profiling approach (Pavkovic et al., 2014a) 74 miRNAs were identified with significantly increased urinary levels 8 and/or 14 days after high dose NTS treatment in both rat strains. For about one-third of these miRNAs kidney expression has already been described (Landgraf et al., 2007; Tian et al., 2008) . Corresponding to the more pronounced pathological findings in WKY rats, a higher number of significantly changed miRNAs associated with higher fold-changes were found in urine from WKY compared with SD rats. Slightly increased urinary levels at lower NTS doses were observed for miR-10b, -21, -34b, -100, and -192 in WKY rats, in parallel to minimal changes seen histopathologically in the corresponding kidneys and increased urinary ALB levels, indicating that they may represent potentially quite sensitive BMs. Nevertheless, none of the urinary miRNA significantly outperformed all protein BMs, thus at least in this study their usefulness as BMs is rather associated with specific information about the localization of injury than with increased sensitivity.
The majority of the urinary miRNAs affected by NTS treatment overlapped with miRNAs described previously to be affected by Cp-induced proximal injury (Pavkovic et al., 2014a) . One explanation is that many identical miRNAs are expressed in different kidney compartments (Kriegel et al., 2013) . As described earlier, a second obvious but not mutually exclusive explanation is that apart from glomerular injury, tubular injury was also present our GN model. Although Cp is an acute toxicant leading to early injury development, we still suggest that the comparison to NTS-induced GN is reasonable because the even the maximal dose of 3 mg/kg Cp caused maximal necrosis on day 8 only. Nevertheless, seemed to be NTS-specific.
Because these 5 were particularly interesting in terms of finding miRNAs specific for glomerular injury, the localization of 2 of them, miR-10b and -100, was investigated within the normal rat kidney by ISH. Contrary to our expectations that they would be expressed in glomeruli, these two were found to be localized in the descending thin limb of the loop of Henle, the distal convoluted tubule, the connecting tubule, and the cortical collecting duct. Yet interestingly, their location partially overlapped with that of the observed tubular lesions. An impairment of these portions of the nephron, in addition to glomerular damage, corresponds to findings by Iida et al. (2014) describing distal nephron segment injuries in rats with anti-GBM GN as well as in patients with Ig A nephropathy (Iida et al., 2014) . Therefore, increased miR-10b and miR-100 levels in urine and detectable but not altered expression in kidney tissue after NTS, instead of indicating direct glomerular injury, may rather indicate leakage out of damaged distal nephron regions, for which qualified and specific BMs are also still missing (Huang et al., 2014) . Furthermore, this would be in line with findings for miR-100 being increased in urine after gentamicin-induced injury affecting proximal and distal convoluted tubules (Nassirpour et al., 2014) but not after Cp-induced proximal tubular injury (Kanki et al., 2014; Pavkovic et al., 2014a) . Ichii et al. (2014) found miR-10b to be abundantly expressed in mouse glomeruli. This apparent contrasting result could be due to species differences or to the fact that their measurement was based on isolated glomeruli only. The same group found miR-26a and -126 as the two most abundantly expressed miRNAs in mouse glomeruli. They also found miR-26a elevated in urine from a murine GN model and from patients with lupus nephritis. We found increased urinary miR-26a levels in both our GN model here, and in our previously reported proximal tubule injury model (Pavkovic et al., 2014a) . Our ISH experiments as well as PCR data from Ichii et al. (2014) indicate that miR-26a is not only exclusively expressed in glomeruli but also in proximal tubules. On the other hand, miR-126 is reported as specifically expressed in endothelial cells (Wang et al., 2008) , which we confirmed by ISH.
We did not observe increased levels of miR-34c, as found by Church et al. (2014) after Doxorubicin-induced glomerular injury. As miR-34-family members can be induced by the DNA damage responsive transcription factor p53, one explanation may be that the measured miR-34c increase by Church et al. may rather be due to DNA damage induced by Doxorubicin, by its action as inhibitor of Topoisomerase 2 (Zunino and Capranico 1990) , and not by glomerular damage in general. This would correspond to an increase of miR-34a in urine and kidney we observed after Cp treatment, which apart from proximal tubular damage induces DNA strand breaks. MiR-34c and miR-34a are two miR-34 family members with the same seed sequence. We did observe, though, an increase of miR-34b in urine and kidneys from WKY rats after NTS treatment. MiR-34b is known to be clustered with miR-34c (miRbase.org), yet which has a different seed sequence for target mRNAs than miR-34c and miR-34a. Besides p53, the miR-34 family is also regulated by other transcription factors, such as Myc or FoxO3a and involved in cell cycle regulation, apoptosis, and epithelial-mesenchymal transition (EMT) (Rokavec et al., 2014) . Therefore, it is possible that different members of the miR-34 family are involved in various functions, including DNA damage response regulation or glomerular injury. Further specific investigations are needed to clarify details.
With respect to miRNAs indicating kidney injury in general, our GN study corroborates previous findings suggesting urinary miR-21 and -192 as promising BMs. Both have conserved sequences in mice, rats, dogs, rhesus monkeys, and humans and are expressed in the kidney (miRBase, 2013). MiR-21 was previously reported as increased in urine form rats with gentamicin-induced kidney injury and renal ischemia-reperfusion injury (Nassirpour et al., 2014; Saikumar et al., 2012) as well as in urine from patients suffering from nephrotic syndrome, diabetic nephropathy, or AKI (Konta et al., 2014; Ramachandran et al., 2013) . Both were found increased early in urine from rats after Cp-induced kidney injury (Kanki et al., 2014; Pavkovic et al., 2014a) . In contrast, these two miRNAs were not increased in urine from rats after methapyrilene-induced liver injury (Pavkovic et al., 2014a) , suggesting specificity concerning kidney versus liver damage.
To obtain insight into molecular processes during GN pathogenesis, mRNA and miRNA expression was investigated in the kidneys after NTS treatment. The immunopathological processes during GN are still not fully understood and likely involve both innate and adaptive immunity (Henique et al., 2014) . In this study, several hundred mRNAs were found deregulated, which functionally were mostly associated with inflammation and regeneration.
The data discussed in this publication have been deposited in NCBI's Gene Expression Omnibus (Edgar et al., 2002) and are accessible through GEO Series accession number GSE64265 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc¼GSE64265).
The b-chain of the major histocompatibility complex class II RT1.B (Rt1-Bb) and C6 were identified as 2 mRNAs differentially expressed between WKY and SD rat strains which could be related to known different susceptibilities to NTS of different rat strains (Kawasaki et al., 1992) ; both were increased in WKY and decreased in SD rats. Increased Rt1-Bb expression in WKY rats could indicate a stronger and more persistent cellular reaction of the adaptive immune system in this strain, in line with findings indicating adaptive immune reactions during GN (Huang et al., 1997; Tam et al., 1999) . The complement cascade is also known to be essential for GN development, especially terminal cascade products like C6 (Nangaku et al., 1997) .
The other major functional category indicated to be affected, regeneration, describes mainly increased expression of genes encoding proteins involved in amino acid synthesis, protein translation, protein transport, and cell adhesion. Some of these mRNAs, which include potential targets for deregulated miRNAs, are reported to be involved in fibrotic pathways. Fibrosis is described to follow glomerular inflammation in a GN model similar to the one used here (Zhou et al., 2010) . TGFb is known as the main cytokine in renal fibrosis (Stahl and Felsen, 2001) , and several mRNAs related to TGFb signaling including those coding for Tgfb2, as well as typical TGFb down-stream targets like transgelin (Tagln, a.k.a. smooth muscle protein 22a) and collagen genes, were increased by NTS treatment. Furthermore, TGFb-dependent EMT was described in proximal tubular and glomerular epithelia cells which could contribute to the development of fibroblasts during GN (Abbate et al., 2002; Marshall et al., 2011) . In line with this, vimentin (Vim) an activated fibroblasts marker, also found in renal biopsies from patients with GN (Bob et al., 2014) , was increased after NTS treatment, whereas predicted miRNA-regulators of Vim mRNA, miR-382-5p, and let-7g, were decreased. A further potential regulatory interaction was found here for decreased matrix Mmp9 mRNA and increased miR-132-3p. The MMP9 protein is an important regulator of extracellular matrix (ECM) degradation, and Kuroda et al. (2004) described that Mmp9 was decreased after NTS treatment as seen here, leading to increased ECM. A regulatory connection between Mmp9 and miR-132-3p was also suggested in an in vitro model for cardiac fibrosis (Jiang et al., 2013) .
Increased miR-21 levels in our GN model may also be associated with fibrotic changes in the kidneys. In a murine model of diabetic nephropathy, also characterized by ECM accumulation, miR-21 was increased in the kidney and its expression correlated positively with Col4 and negatively with Mmp9 as seen in our GN model. Very recent findings on miR-21 function in glomerular injury indicate a protective role of miR-21 as a feedback inhibitor of TGFb1 signaling and functions (Lai et al., 2014) In summary, we found a considerable number of urinary miRNAs increased after NTS-induced GN with stronger changes overall in WKY versus SD rats, confirming the former as more appropriate to study GN. By comparison of GN-associated urinary miRNA profiles with those after Cp-induced tubular injury, we found that most had similar profiles, due to also observed tubular injury in our GN model and many miRNAs likely being expressed broadly in the kidney. Still, 5 miRNAs could be identified as being potentially GN-specific miRNAs. Investigation of the localization of two of these, miR-10b and -100, by ISH in the normal kidney revealed their expression within distal nephron segments. Thus, although appearance of these two miRNAs in urine apparently does not indicate glomerular damage, they may represent BMs for distal tubular injury. Finally, potential mRNA-miRNA regulatory interactions associated with GN are suggested from their expression profiles in kidney.
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